Metabolic activity of breast cancer metastatic lesions on positron emission tomography/computed tomography: comparison with histological and biological characteristics of primary tumor

• Published in: Neoplasma Vol. 63; no. 2; p. 313
• Main Authors: Sobic Saranovic, D, Stojiljkovic, M, Susnjar, S, Odalovic, S, Artiko, V, Pavlovic, S, Grozdic-Milojevic, I, Obradovic, V
• Format: Journal Article
• Language: English
• Published: Slovakia 01-01-2016
• Subjects: Bone Neoplasms - metabolism; Bone Neoplasms - secondary; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - pathology; Energy Metabolism - physiology; Female; Fluorodeoxyglucose F18 - metabolism; Glucose - metabolism; Humans; Ki-67 Antigen - metabolism; Liver Neoplasms - metabolism; Liver Neoplasms - secondary; Lymph Nodes - metabolism; Lymphatic Metastasis - pathology; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals - metabolism; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; SUVmax; breast cancer; metabolism; positron emission tomography; metastasis
• ISSN: 0028-2685
• DOI: 10.4149/219_150813N440

Higher intensity of FDG uptake on PET/CT in primary tumor is seen in patients with IDC compared to ILC, also in high grade tumours, tumours with negative ER and higher Ki67 values, while data are inconsistent in case of relation between primary tumor's PgR and HER2 expression with its metabolic activity levels. On account of the lack of studies that include research of breast cancer metastatic lesion metabolism level and its relation to tumor histology and biology, our goal was to investigate the association of metastatic lesions' glucose metabolism level on PET/CT with different histological and biological characteristics of primary tumor. In a total number of N=100 patients, highest SUVmax values for each patient were used in testing difference between metastatic metabolic activity in patients with different tumor histology, grade, ER, PgR and HER2 status, subtype, as well in testing relation of Ki67 index to metastasis' metabolism level. In testing difference between histological types of breast cancer, SUVmax values were also compared separately for each specific anatomical site (regional and distant lymph nodes, bones and liver). No difference was found regarding metastatic SUVmax values in patients with primary IDC (n=55, median SUVmax 9.70) and ILC (n=34, median SUVmax 7.20) independently of anatomic site, and for each of analysed sites separately. No difference was found as well between SUVmax detected in metastasis in patients with different grade (grade II: n=58, median SUVmax 7.70; grade III: n=12, median SUVmax 10.20), ER (59 positive, median SUVmax 8.50; 22 negative, median SUVmax 8.05), PgR (55 positive, median SUVmax 8.50; 23 negative, median SUVmax 7.80), and HER2 (14 positive, median SUVmax 6.84; 51 negative, median SUVmax 8.63) expression in primary tumor, and between patients with different tumor subtype. Ki67 was also not associated with tumor metastatic SUVmax values (n=11, rs = -0.21, p=0.53). We conclude that there is no association of primary breast cancer histological type, grade, ER, PgR, HER2 and Ki67 expression with metabolic activity in metastasis detected on PET/CT.